Earnings History Data for Trillium Therapeutics Inc. (TRIL) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Trillium Therapeutics Inc.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (`do not eat`) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (`eat`) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-08-2021 | PM | After the close (Aug 12) |
TRIL | Trillium Therapeutics Inc. | 658.00 | -0.18 | -0.16 | 0.00 | Trillium Therapeutics EPS misses by $0.04 [8/13/2021 7:10 AM] |
6.24 | 0.14 (2.21%) |
6.18 | 0.08 (1.31%) |
5.99 - 20.96 | 736,515 | 770,000 | 1,538 | |
| 07-05-2021 | PM | TRIL | Trillium Therapeutics Inc. | 1,028 | -0.11 | -0.18 | 0.00 | 9.59 | 0.30 (3.23%) |
9.59 | 0.0 (0.00%) |
5.20 - 20.96 | 1,274,191 | 2,540,000 | 1,187 | |||
| 18-03-2021 | AH | After the close (Mar 18) |
TRIL | Trillium Therapeutics Inc. | 1,111 | -0.25 | -0.14 | 0.00 | 11.10 | 0.63 (6.02%) |
10.66 | 0.19 (1.81%) |
2.50 - 20.96 | 1,573,890 | 1,270,000 | 9,098 | ||
| 15-05-2020 | AH | TRIL | Trillium Therapeutics Inc. | 489.97 | -0.23 | -0.09 | -0.46 | Trillium Therapeutics EPS misses by $0.97 [5/15/2020 5:04 PM] |
6.82 | -0.23 (-3.26%) |
6.73 | -0.09 (-1.32%) |
0.24 - 7.97 | 2,395,999 | 2,763,694 | 4,917 | ||
|
|
||||||||||||||||||